|Regado Biosciences, Inc.|
120 Mountain View Boulevard
United States - Map
|Full Time Employees:||27|
Regado Biosciences, Inc., a biopharmaceutical company, focuses on the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular, and other indications. Its lead product includes REG1, an anticoagulant that is in Phase IIb clinical trials for use in patients with various cardiovascular conditions undergoing percutaneous coronary intervention. The companys products under development also comprise REG2, which is in Phase I clinical trials for the venous thrombosis indications treatment; and REG3, a preclinical stage antiplatelet therapy consisting of glycoprotein VI inhibitor for diabetic vasculopathy and other inflammatory diseases. The company was formerly known as Quartet Biosciences, Inc. and changed its name to Regado Biosciences, Inc. in March 2003. Regado Biosciences, Inc. was founded in 2001 and is headquartered in Basking Ridge, New Jersey.
|Dr. David J. Mazzo B.A (Hons), B.Sc. (Hons.), M.Sc., Ph.D.,
Chief Exec. Officer and Director
|Dr. Christopher P. Rusconi Ph.D.,
Co-Founder, Chief Scientific Officer, Sr. VP of Discovery, Sr. VP of Preclinical Devel. and Sec.
|Dr. Steven L. Zelenkofske M.D.,
Chief Medical Officer and Sr. VP of Clinical & Medical Affairs
|Mr. Michael A. Metzger M.B.A.,
Pres and Chief Operating Officer
|Mr. Christopher E. Courts MBA CPA,
Principal Financial Officer, Principal Accounting Officer and VP of Fin.
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|